Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare

Core Insights - Tevogen Bio Holdings Inc. supports the White House's AI Action Plan, emphasizing the need for domain-specific standards and regulatory frameworks in healthcare AI [1][2] - The company has developed PredicTcell™, a machine learning model that accelerates immunotherapy research, potentially saving billions in drug development costs [2][3] - Tevogen aims to provide scalable and ethical solutions to enhance access to advanced therapeutics for all Americans, aligning with the government's focus on innovation and equity [3] Company Developments - Tevogen.AI's collaboration with Microsoft and Databricks has led to the creation of the alpha version of PredicTcell™, which significantly reduces the time for target analysis in immunotherapy [2] - The model's development reflects the AI Action Plan's goals for rapid scientific innovation and improved AI adoption in healthcare [2] Industry Context - The AI Action Plan highlights the importance of building trust and governance in healthcare AI, which is crucial for the industry's growth and regulatory compliance [1] - Tevogen's initiatives align with the federal government's strategy to leverage AI for enhancing healthcare delivery and reducing costs [3]